Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Neurotrophic Keratitis Market


4. Market Overview

4.1. Introduction

4.1.1. Treatment Type Definition

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Neurotrophic Keratitis Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porter’s Five Force Analysis


5. Market Outlook

5.1. Disease Prevalence & Incidence Rate globally with key countries / Region

5.2. Pipeline Analysis

5.3. Key Industry Developments


6. Global Neurotrophic Keratitis Market Analysis and Forecast, by Treatment Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Treatment Type, 2017–2027

6.3.1. Drugs

6.3.1.1. Artificial Tears

6.3.1.2. Recombinant Human Nerve Growth Factors Eye Drop

6.3.1.3. Oral Antibiotics

6.3.1.4. Bandage Contact Lens

6.3.1.5. Others

6.3.2. Surgical Intervention

6.3.2.1. Tarsorrhaphy

6.3.2.2. Amniotic Membrane Transplantation

6.3.2.3. Others

6.4. Market Attractiveness, by Treatment Type


7. Global Neurotrophic Keratitis Market Analysis and Forecast, by Stage

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Stage, 2017–2027

7.3.1. Stage I

7.3.2. Stage II

7.3.3. Stage III

7.4. Market Attractiveness Analysis, by Stage


8. Global Neurotrophic Keratitis Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness Analysis, by Country/Region


9. North America Neurotrophic Keratitis Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast By Treatment Type, 2017–2027

9.2.1. Drugs

9.2.1.1. Artificial Tears

9.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

9.2.1.3. Oral Antibiotics

9.2.1.4. Bandage Contact Lens

9.2.1.5. Others

9.2.2. Surgical Intervention

9.2.2.1. Tarsorrhaphy

9.2.2.2. Amniotic Membrane Transplantation

9.2.2.3. Others

9.3. Market Value Forecast, by Stage, 2017–2027

9.3.1. Stage I

9.3.2. Stage II

9.3.3. Stage III

9.4. Market Value Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Treatment Type

9.5.2. By Stage

9.5.3. By Country


10. Europe Neurotrophic Keratitis Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Treatment Type, 2017–2027

10.2.1. Drugs

10.2.1.1. Artificial Tears

10.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

10.2.1.3. Oral Antibiotics

10.2.1.4. Bandage Contact Lens

10.2.1.5. Others

10.2.2. Surgical Intervention

10.2.2.1. Tarsorrhaphy

10.2.2.2. Amniotic Membrane Transplantation

10.2.2.3. Others

10.3. Market Value Forecast, by Stage, 2017–2027

10.3.1. Stage I

10.3.2. Stage II

10.3.3. Stage III

10.4. Market Value Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis

10.5.1. By Treatment Type

10.5.2. By Stage

10.5.3. By Country/Sub-region


11. Asia Pacific Neurotrophic Keratitis Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Treatment Type, 2017–2027

11.2.1. Drugs

11.2.1.1. Artificial Tears

11.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

11.2.1.3. Oral Antibiotics

11.2.1.4. Bandage Contact Lens

11.2.1.5. Others

11.2.2. Surgical Intervention

11.2.2.1. Tarsorrhaphy

11.2.2.2. Amniotic Membrane Transplantation

11.2.2.3. Others

11.3. Market Value Forecast, by Stage, 2017–2027

11.3.1. Stage I

11.3.2. Stage II

11.3.3. Stage III

11.4. Market Value Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis

11.5.1. By Treatment Type

11.5.2. By Stage

11.5.3. By Country/Sub-region

12. Latin America Neurotrophic Keratitis Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Treatment Type, 2017–2027

12.2.1. Drugs

12.2.1.1. Artificial Tears

12.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

12.2.1.3. Oral Antibiotics

12.2.1.4. Bandage Contact Lens

12.2.1.5. Others

12.2.2. Surgical Intervention

12.2.2.1. Tarsorrhaphy

12.2.2.2. Amniotic Membrane Transplantation

12.2.2.3. Others

12.3. Market Value Forecast, by Stage, 2017–2027

12.3.1. Stage I

12.3.2. Stage II

12.3.3. Stage III

12.4. Market Value Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis

12.5.1. By Treatment Type

12.5.2. By Stage

12.5.3. By Country/Sub-region

13. Middle East & Africa Neurotrophic Keratitis Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Treatment Type, 2017–2027

13.2.1. Drugs

13.2.1.1. Artificial Tears

13.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

13.2.1.3. Oral Antibiotics

13.2.1.4. Bandage Contact Lens

13.2.1.5. Others

13.2.2. Surgical Intervention

13.2.2.1. Tarsorrhaphy

13.2.2.2. Amniotic Membrane Transplantation

13.2.2.3. Others

13.3. Market Value Forecast, by Stage, 2017–2027

13.3.1. Stage I

13.3.2. Stage II

13.3.3. Stage III

13.4. Market Value Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis

13.5.1. By Treatment Type

13.5.2. By Stage

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competition Matrix (By Tier and Size of companies)

14.2. Market Share/Position Analysis, by Company, 2018

14.3. Company Profiles

14.3.1. Dompe farmaceutici S.p.A.

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Growth Strategies

14.3.1.3. SWOT Analysis

14.3.2. Allergan

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Growth Strategies

14.3.2.3. SWOT Analysis

14.3.3. ReGenTree, LLC

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Growth Strategies

14.3.3.3. SWOT Analysis

14.3.4. Alcon

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Growth Strategies

14.3.4.3. SWOT Analysis

14.3.5. Bausch & Lomb Incorporated (Bausch Health Companies Inc.)

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Growth Strategies

14.3.5.3. SWOT Analysis

14.3.6. CONTACARE

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Growth Strategies

14.3.6.3. SWOT Analysis

14.3.7. ROHTO Pharmaceutical Co., Ltd.

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Growth Strategies

14.3.7.3. SWOT Analysis

14.3.8. Pfizer, Inc.

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Growth Strategies

14.3.8.3. SWOT Analysis

14.3.9. Neuroptika

14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.9.2. Growth Strategies

14.3.9.3. SWOT Analysis

14.3.10. Santen Pharmaceutical Co., Ltd.

14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.10.2. Growth Strategies

14.3.10.3. SWOT Analysis

14.3.11. Johnson & Johnson

14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.11.2. Growth Strategies

14.3.11.3. SWOT Analysis

14.3.12. Grand Pharma (China) Co., Ltd.

14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.12.2. Growth Strategies

14.3.12.3. SWOT Analysis

14.3.13. Zhejiang CONBA Pharmaceutical Co., Ltd.

14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.13.2. Growth Strategies

14.3.13.3. SWOT Analysis



List of Figures



Figure 01: Global Neurotrophic Keratitis Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Neurotrophic Keratitis Market Value (US$ Mn), by Treatment Type, 2018 (A)

Figure 03: Global Neurotrophic Keratitis Market, Top 3 Trends, 2018

Figure 04: Market Overview

Figure 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, 2017–2027

Figure 06: Global Neurotrophic Keratitis Market Value Share, by Treatment Type, 2018

Figure 07: Global Neurotrophic Keratitis Market Value Share, by Stage, 2018

Figure 08: Global Neurotrophic Keratitis Market Value Share, by Region, 2018

Figure 09: Global Neurotrophic Keratitis Market Value Share, by Drugs, 2018

Figure 10: Global Neurotrophic Keratitis Market Value Share, by Surgical Intervention, 2018

Figure 11: Global Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 12: Global Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 13: Global Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 14: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Drugs, 2017–2027

Figure 15: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Surgical Intervention, 2017–2027

Figure 16: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 17: Global Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 18: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage I, 2017–2027

Figure 19: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage II, 2017–2027

Figure 20: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage III, 2017–2027

Figure 21: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 22: Global Neurotrophic Keratitis Market Value Share Analysis, by Region, 2018 and 2027

Figure 23: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Region, 2019–2027

Figure 24: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 25: North America Neurotrophic Keratitis Market Value Share Analysis, by Country, 2018 and 2027

Figure 26: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Country, 2019–2027

Figure 27: North America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 28: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 29: North America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 30: North America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 31: North America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 32: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 33: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 34: Europe Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 35: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 36: Europe Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 37: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 38: Europe Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 39: Europe Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 40: Europe Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 41: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 42: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 43: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 44: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 45: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 46: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 47: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 48: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 49: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 50: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 51: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 52: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 54: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 55: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 56: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 57: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 58: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 59: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 60: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 61: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 62: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 63: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 64: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 65: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 66: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 67: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 68: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 69: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company


List of Tables



Table 01: Neurotrophic Keratitis Pipeline Analysis - Phase III and Phase II

Table 02: Neurotrophic Keratitis Pipeline Analysis - Phase I

Table 03: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 04: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 06: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 07: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 09: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 10: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 11: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 12: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 13: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 14: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 15: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 16: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 17: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 18: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 20: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 21: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 22: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 23: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 24: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 25: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 26: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 27: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 28: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 29: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 30: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 31: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 32: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027